Mertens W C, Bramwell V H
Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, MI 48201, USA.
Curr Opin Oncol. 1996 Jul;8(4):299-304. doi: 10.1097/00001622-199607000-00006.
Steady progress in the delineation of prognostic factors and the identification of genetic alterations and of potential mechanisms of oncogenesis mark the contributions to the literature on osteosarcoma for the past year. A new cytokine and chemotherapy combination has shown promise, and additional work on chemotherapy regimens containing ifosfamide will undoubtedly stimulate interest in a new generation of randomized clinical trials that will be essential for further refinement of therapy for osteosarcoma.